TransMedics Group, Inc. (TMDX)

Market Cap	3.61B +52.5%
Revenue (ttm)	605.49M +37.1%
Net Income	190.29M +436.6%
EPS	4.87 +382.5%
Shares Out	34.30M
PE Ratio	21.60
Forward PE	42.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	198,007
Open	101.08
Previous Close	100.70
Day's Range	101.08 - 105.50
52-Week Range	62.23 - 156.00
Beta	1.95
Analysts	Buy
Price Target	154.00 (+46.32%)
Earnings Date	May 7, 2026

About TMDX

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 2, 2019
• Employees: 898
• Stock Exchange: NASDAQ
• Ticker Symbol: TMDX
• Website: https://www.transmedics.com

Financial Performance

In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.

Analyst Summary

According to 9 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price target is $154.0, which is an increase of 46.32% from the latest price.

Price Target

$154.0

(46.32% upside)

Analyst Consensus: Buy